Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Source: 
Endpoints
snippet: 

Novartis is rolling out new data that build on its case for the company’s blockbuster hopeful RTH258, an investigational therapy that might carve away a considerable chunk of Regeneron’s $5 billion Eylea franchise if approved.